Ryan & Maniskas, LLP Announces Investigation of Auxilium Pharmaceuticals Inc.

Loading...
Loading...

WAYNE, Pa., Oct. 14, 2014 /PRNewswire/ -- Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Auxilium Pharmaceuticals Inc. ("Auxilium" or the "Company") AUXL concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Endo International Plc ("Endo") for approximately $2.6 billion.

If you own shares of Auxilium and would like to learn more about this class action or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/auxl.  You may also email Mr. Maniskas at rmaniskas@rmclasslaw.com

Under the terms of the agreement, shareholders of Auxilium may elect to receive a combination of $16.625 in cash plus 0.2440 Endo ordinary shares, $33.25 in cash, or 0.4880 Endo ordinary shares for each share of Auxilium stock they own.

Our investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Auxilium for not acting in the Company's shareholders' best interests in connection with the sale process. 

Ryan & Maniskas, LLP is a national shareholder litigation firm.  Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.  To learn more about the class action process, please visit: www.rmclasslaw.com.

CONTACT:    Ryan & Maniskas, LLP
Richard A. Maniskas, Esquire
995 Old Eagle School Rd., Suite 311
Wayne, PA 19087
877-316-3218
www.rmclasslaw.com/cases/auxl      
rmaniskas@rmclasslaw.com 

Logo - http://photos.prnewswire.com/prnh/20121112/MM11729LOGO

SOURCE Ryan & Maniskas, LLP

Loading...
Loading...
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...